-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind Medicine Files Israeli Patent Application For Combination Therapy Of 5-Methoxy-2-Aminoindane And N-Acylethanolamines, Addressing Depression

Benzinga·11/17/2025 12:57:27
Listen to the news

Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of an Israeli patent application for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), addressing depression.

The patent application stems from Clearmind's collaboration with Neurothera Labs Inc. (TSXV:NTLX) ("Neurothera"), a subsidiary of SciSparc Ltd. (NASDAQ:SPRC). This therapy targets depression treatment using the combination of MEAI and PEA. According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability, with limited innovative treatment options available.

This new filing expands Clearmind's growing intellectual property portfolio. The Company has filed 13 patents related to its collaboration with Neurothera, focusing, among others, on MEAI and N-Acylethanolamines combinations for conditions such as alcohol use disorder, cocaine addiction, obesity and weight loss, and depression. Preclinical data supports MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.